Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Organigram Global Inc.NASDAQ: OGI

Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of CA$5.05M rose 4.3% year over year, behind the +37.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.4% from the prior quarter.

Context

  • Depreciation & amortization amounted to 9.7% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.3% toward the trailing-twelve-month pace of +37.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$5.05M+1.4% QoQ
Last fiscal yearSep 2025
CA$17.98M+48.8% YoY
LTMMar 2026
CA$19.77M+37.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%——
1 year+48.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the cash flow

Latest · FY2025
17.98M CAD
Year-over-year change
+48.8%
4-year CAGR
-12.8%

Depreciation & Amortization vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.9% is the 2nd highest of 9, against a peer median of +9.1%.
  • Depreciation & amortization amounts to 7.2% of revenue for OGI, versus a peer median of 7.0%.
OGI Competitors
Depreciation & Amortization for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$19.77M CAD+37.9%—7.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$14.19M CAD-37.1%-31.1%4.6%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$13.25M USD+2.4%-0.2%9.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$9.76M USD—-23.7%7.2%
DERMJourney Medical CorporationLTM Mar 2026$4.41M USD+17.1%+2.7%6.8%
IVAInventiva S.A.FY2025€3.22M EUR-38.0%+23.8%71.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$2.42M USD+13.1%+32.0%136.2%
ELMDElectromed, Inc.LTM Mar 2026$1.11M USD+12.8%+23.1%1.5%
HSDTSolana CompanyLTM Mar 2026$672K USD+1192.3%+30.5%7.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K USD+5.4%+13.8%1.0%
Peer median (excluding OGI) —+9.1%+13.8%7.0%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.08M12.08M17.98M
Deferred Income Tax42.21M(88K)(2.66M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(4.06M)27.02M13.16M
Other Non-Cash Items776K(29M)151.8M15.09M14.16M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(4.3M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(12.22M)
Acquisitions (Net)(2.54M)(11.06M)00(65.62M)
Purchases of Investments(120.02M)(15M)(7.36M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M36.37M3.52M2.5M
Other Investing Activities(31.08M)4.29M31.46M(8.32M)21.8M
Investing Cash Flow(115.11M)44.03M4.56M(38.77M)(59.35M)
Debt Repayment(116.4M)(1.01M)(64.04K)(786K)(43.08K)
Common Stock Issued284.88M6.34M20K108.56M29.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(754.15K)6K(1.29M)
Financing Cash Flow174.46M5.33M(754.15K)107.78M28.24M
Effect of Forex Changes0000(2.57M)
Net Change in Cash30.77M13.15M(68.52M)72.88M(37.98M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(16.52M)

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.